Annonce • May 29
Sundrug Co.,Ltd. to Report Q1, 2027 Results on Aug 14, 2026 Sundrug Co.,Ltd. announced that they will report Q1, 2027 results on Aug 14, 2026 Reported Earnings • May 20
Full year 2026 earnings: EPS misses analyst expectations Full year 2026 results: EPS: JP¥268 (up from JP¥263 in FY 2025). Revenue: JP¥842.5b (up 5.1% from FY 2025). Net income: JP¥31.4b (up 2.1% from FY 2025). Profit margin: 3.7% (down from 3.8% in FY 2025). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 1.0%. Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 5.1% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Annonce • May 15
Sundrug Co.,Ltd., Annual General Meeting, Jun 27, 2026 Sundrug Co.,Ltd., Annual General Meeting, Jun 27, 2026. Annonce • May 09
Sundrug Co.,Ltd. to Report Fiscal Year 2026 Results on May 15, 2026 Sundrug Co.,Ltd. announced that they will report fiscal year 2026 results on May 15, 2026 Upcoming Dividend • Mar 23
Upcoming dividend of JP¥66.00 per share Eligible shareholders must have bought the stock before 30 March 2026. Payment date: 23 June 2026. Payout ratio is a comfortable 49% but the company is paying out more than the cash it is generating. Trailing yield: 3.4%. Lower than top quartile of Japanese dividend payers (3.6%). Higher than average of industry peers (1.7%). Reported Earnings • Feb 14
Third quarter 2026 earnings: EPS misses analyst expectations Third quarter 2026 results: EPS: JP¥76.61 (down from JP¥81.73 in 3Q 2025). Revenue: JP¥217.3b (up 4.5% from 3Q 2025). Net income: JP¥8.96b (down 6.3% from 3Q 2025). Profit margin: 4.1% (down from 4.6% in 3Q 2025). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 7.9%. Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 5.3% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 5% per year. Declared Dividend • Dec 02
First half dividend of JP¥66.00 announced Shareholders will receive a dividend of JP¥66.00. Ex-date: 30th March 2026 Payment date: 23rd June 2026 Dividend yield will be 3.0%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by earnings (48% earnings payout ratio) but not covered by cash flows (157% cash payout ratio). The dividend has increased by an average of 16% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 17% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Annonce • Nov 29
Sundrug Co.,Ltd. to Report Q3, 2026 Results on Feb 12, 2026 Sundrug Co.,Ltd. announced that they will report Q3, 2026 results on Feb 12, 2026 Reported Earnings • Nov 18
Second quarter 2026 earnings: EPS exceeds analyst expectations Second quarter 2026 results: EPS: JP¥62.62 (up from JP¥59.68 in 2Q 2025). Revenue: JP¥210.7b (up 4.8% from 2Q 2025). Net income: JP¥7.33b (up 4.9% from 2Q 2025). Profit margin: 3.5% (in line with 2Q 2025). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 4.0%. Revenue is forecast to grow 5.9% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 9% per year whereas the company’s share price has increased by 4% per year. Upcoming Dividend • Sep 22
Upcoming dividend of JP¥65.00 per share Eligible shareholders must have bought the stock before 29 September 2025. Payment date: 10 December 2025. Payout ratio is a comfortable 48% but the company is paying out more than the cash it is generating. Trailing yield: 3.0%. Lower than top quartile of Japanese dividend payers (3.6%). Higher than average of industry peers (1.6%). Annonce • Sep 02
Sundrug Co.,Ltd. to Report Q2, 2026 Results on Nov 14, 2025 Sundrug Co.,Ltd. announced that they will report Q2, 2026 results on Nov 14, 2025 Reported Earnings • Aug 15
First quarter 2026 earnings: Revenues and EPS in line with analyst expectations First quarter 2026 results: EPS: JP¥67.92 (up from JP¥62.33 in 1Q 2025). Revenue: JP¥207.7b (up 6.7% from 1Q 2025). Net income: JP¥7.94b (up 9.0% from 1Q 2025). Profit margin: 3.8% (up from 3.7% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Revenue is forecast to grow 5.8% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 10% per year whereas the company’s share price has increased by 11% per year. Declared Dividend • Jul 09
Final dividend of JP¥65.00 announced Shareholders will receive a dividend of JP¥65.00. Ex-date: 29th September 2025 Payment date: 10th December 2025 Dividend yield will be 2.9%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by earnings (22% earnings payout ratio) but not covered by cash flows (222% cash payout ratio). The dividend has increased by an average of 16% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 18% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Jun 24
Full year 2025 earnings: EPS exceeds analyst expectations Full year 2025 results: EPS: JP¥263 (up from JP¥249 in FY 2024). Revenue: JP¥801.8b (up 6.7% from FY 2024). Net income: JP¥30.8b (up 5.6% from FY 2024). Profit margin: 3.8% (down from 3.9% in FY 2024). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.3%. Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 1.5% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 10% per year whereas the company’s share price has increased by 15% per year. Annonce • May 31
Sundrug Co.,Ltd. to Report Q1, 2026 Results on Aug 14, 2025 Sundrug Co.,Ltd. announced that they will report Q1, 2026 results on Aug 14, 2025 Reported Earnings • May 20
Full year 2025 earnings: EPS exceeds analyst expectations Full year 2025 results: EPS: JP¥263 (up from JP¥249 in FY 2024). Revenue: JP¥801.8b (up 6.7% from FY 2024). Net income: JP¥30.8b (up 5.6% from FY 2024). Profit margin: 3.8% (down from 3.9% in FY 2024). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.3%. Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 2.6% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has increased by 18% per year, which means it is tracking significantly ahead of earnings growth. Annonce • May 15
Sundrug Co.,Ltd., Annual General Meeting, Jun 20, 2025 Sundrug Co.,Ltd., Annual General Meeting, Jun 20, 2025. Upcoming Dividend • Mar 21
Upcoming dividend of JP¥65.00 per share Eligible shareholders must have bought the stock before 28 March 2025. Payment date: 24 June 2025. Payout ratio is a comfortable 22% but the company is paying out more than the cash it is generating. Trailing yield: 3.1%. Lower than top quartile of Japanese dividend payers (3.7%). Higher than average of industry peers (1.7%). Annonce • Mar 01
Sundrug Co.,Ltd. to Report Fiscal Year 2025 Results on May 15, 2025 Sundrug Co.,Ltd. announced that they will report fiscal year 2025 results on May 15, 2025 Reported Earnings • Feb 16
Third quarter 2025 earnings: EPS exceeds analyst expectations Third quarter 2025 results: EPS: JP¥81.73 (up from JP¥74.62 in 3Q 2024). Revenue: JP¥208.0b (up 7.1% from 3Q 2024). Net income: JP¥9.56b (up 9.5% from 3Q 2024). Profit margin: 4.6% (up from 4.5% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 5.5%. Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 9% per year and the company’s share price has also increased by 9% per year. Buy Or Sell Opportunity • Feb 06
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 8.6% to JP¥4,076. The fair value is estimated to be JP¥3,391, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 6.9% over the last 3 years. Earnings per share has grown by 8.6%. For the next 3 years, revenue is forecast to grow by 6.1% per annum. Earnings are also forecast to grow by 6.1% per annum over the same time period. Buy Or Sell Opportunity • Jan 07
Now 21% overvalued The stock has been flat over the last 90 days, currently trading at JP¥4,093. The fair value is estimated to be JP¥3,388, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 6.9% over the last 3 years. Earnings per share has grown by 8.6%. For the next 3 years, revenue is forecast to grow by 5.9% per annum. Earnings are also forecast to grow by 5.7% per annum over the same time period. Declared Dividend • Dec 11
First half dividend of JP¥65.00 announced Shareholders will receive a dividend of JP¥65.00. Ex-date: 28th March 2025 Payment date: 24th June 2025 Dividend yield will be 3.3%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by earnings (49% earnings payout ratio) but not covered by cash flows (dividend approximately 7x free cash flows). The dividend has increased by an average of 17% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 19% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Annonce • Dec 03
Sundrug Co.,Ltd. to Report Q3, 2025 Results on Feb 14, 2025 Sundrug Co.,Ltd. announced that they will report Q3, 2025 results on Feb 14, 2025 Reported Earnings • Nov 20
Second quarter 2025 earnings: EPS misses analyst expectations Second quarter 2025 results: EPS: JP¥59.68 (down from JP¥61.17 in 2Q 2024). Revenue: JP¥201.0b (up 6.0% from 2Q 2024). Net income: JP¥6.98b (down 2.4% from 2Q 2024). Profit margin: 3.5% (down from 3.8% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 9.7%. Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 2.5% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Upcoming Dividend • Sep 20
Upcoming dividend of JP¥65.00 per share Eligible shareholders must have bought the stock before 27 September 2024. Payment date: 04 December 2024. Payout ratio is a comfortable 45% but the company is paying out more than the cash it is generating. Trailing yield: 3.2%. Lower than top quartile of Japanese dividend payers (3.8%). Higher than average of industry peers (1.6%). Annonce • Aug 28
Sundrug Co.,Ltd. to Report Q2, 2025 Results on Nov 14, 2024 Sundrug Co.,Ltd. announced that they will report Q2, 2025 results on Nov 14, 2024 Reported Earnings • Aug 19
First quarter 2025 earnings: EPS exceeds analyst expectations First quarter 2025 results: EPS: JP¥62.33 (up from JP¥59.01 in 1Q 2024). Revenue: JP¥194.6b (up 6.8% from 1Q 2024). Net income: JP¥7.29b (up 5.7% from 1Q 2024). Profit margin: 3.7% (down from 3.8% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.7%. Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 4% per year. Declared Dividend • Jul 11
Final dividend increased to JP¥65.00 Dividend of JP¥65.00 is 14% higher than last year. Ex-date: 27th September 2024 Payment date: 4th December 2024 Dividend yield will be 3.1%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by earnings (44% earnings payout ratio) but not covered by cash flows (dividend approximately 5x free cash flows). The dividend has increased by an average of 17% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 18% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Jun 28
Full year 2024 earnings: EPS exceeds analyst expectations Full year 2024 results: EPS: JP¥249 (up from JP¥220 in FY 2023). Revenue: JP¥751.8b (up 8.9% from FY 2023). Net income: JP¥29.1b (up 13% from FY 2023). Profit margin: 3.9% (up from 3.7% in FY 2023). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.5%. Revenue is forecast to grow 5.9% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 5% per year and the company’s share price has also increased by 5% per year. Annonce • Jun 02
Sundrug Co.,Ltd. to Report Q1, 2025 Results on Aug 14, 2024 Sundrug Co.,Ltd. announced that they will report Q1, 2025 results on Aug 14, 2024 Reported Earnings • May 20
Full year 2024 earnings: EPS exceeds analyst expectations Full year 2024 results: EPS: JP¥249 (up from JP¥220 in FY 2023). Revenue: JP¥751.8b (up 8.9% from FY 2023). Net income: JP¥29.1b (up 13% from FY 2023). Profit margin: 3.9% (up from 3.7% in FY 2023). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.6%. Revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 4% per year. Annonce • May 17
Sundrug Co.,Ltd., Annual General Meeting, Jun 21, 2024 Sundrug Co.,Ltd., Annual General Meeting, Jun 21, 2024. Buy Or Sell Opportunity • Mar 22
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 8.6% to JP¥4,870. The fair value is estimated to be JP¥4,027, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.0% over the last 3 years. Earnings per share has grown by 3.2%. For the next 3 years, revenue is forecast to grow by 6.4% per annum. Earnings are also forecast to grow by 8.0% per annum over the same time period. Upcoming Dividend • Mar 21
Upcoming dividend of JP¥57.00 per share Eligible shareholders must have bought the stock before 28 March 2024. Payment date: 26 June 2024. Payout ratio is a comfortable 44% but the company is paying out more than the cash it is generating. Trailing yield: 2.4%. Lower than top quartile of Japanese dividend payers (3.2%). Higher than average of industry peers (1.5%). Buy Or Sell Opportunity • Mar 07
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 7.1% to JP¥4,846. The fair value is estimated to be JP¥4,027, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.0% over the last 3 years. Earnings per share has grown by 3.2%. For the next 3 years, revenue is forecast to grow by 6.4% per annum. Earnings are also forecast to grow by 8.0% per annum over the same time period. Annonce • Mar 02
Sundrug Co.,Ltd. to Report Fiscal Year 2024 Results on May 15, 2024 Sundrug Co.,Ltd. announced that they will report fiscal year 2024 results on May 15, 2024 Reported Earnings • Feb 16
Third quarter 2024 earnings: Revenues and EPS in line with analyst expectations Third quarter 2024 results: EPS: JP¥74.62 (up from JP¥65.36 in 3Q 2023). Revenue: JP¥194.3b (up 7.7% from 3Q 2023). Net income: JP¥8.73b (up 14% from 3Q 2023). Profit margin: 4.5% (up from 4.2% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 2.7% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 3% per year and the company’s share price has also increased by 3% per year. Annonce • Nov 27
Sundrug Co.,Ltd. to Report Q3, 2024 Results on Feb 14, 2024 Sundrug Co.,Ltd. announced that they will report Q3, 2024 results on Feb 14, 2024 Reported Earnings • Nov 17
Second quarter 2024 earnings: EPS and revenues exceed analyst expectations Second quarter 2024 results: EPS: JP¥61.17 (up from JP¥54.94 in 2Q 2023). Revenue: JP¥189.6b (up 9.7% from 2Q 2023). Net income: JP¥7.15b (up 11% from 2Q 2023). Profit margin: 3.8% (up from 3.7% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.2%. Earnings per share (EPS) also surpassed analyst estimates by 3.4%. Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 2.7% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has increased by 1% per year. Upcoming Dividend • Sep 21
Upcoming dividend of JP¥57.00 per share at 2.7% yield Eligible shareholders must have bought the stock before 28 September 2023. Payment date: 05 December 2023. Payout ratio is a comfortable 44% and the cash payout ratio is 89%. Trailing yield: 2.7%. Lower than top quartile of Japanese dividend payers (3.3%). Higher than average of industry peers (1.6%). Annonce • Aug 27
Sundrug Co.,Ltd. to Report Q2, 2024 Results on Nov 14, 2023 Sundrug Co.,Ltd. announced that they will report Q2, 2024 results on Nov 14, 2023 Reported Earnings • Aug 12
First quarter 2024 earnings released: EPS: JP¥59.01 (vs JP¥53.86 in 1Q 2023) First quarter 2024 results: EPS: JP¥59.01 (up from JP¥53.86 in 1Q 2023). Revenue: JP¥182.1b (up 9.4% from 1Q 2023). Net income: JP¥6.90b (up 9.6% from 1Q 2023). Profit margin: 3.8% (in line with 1Q 2023). Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 2.5% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has increased by 3% per year. Annonce • May 31
Sundrug Co.,Ltd. to Report Q1, 2024 Results on Aug 10, 2023 Sundrug Co.,Ltd. announced that they will report Q1, 2024 results on Aug 10, 2023 Annonce • May 17
Sundrug Co.,Ltd., Annual General Meeting, Jun 23, 2023 Sundrug Co.,Ltd., Annual General Meeting, Jun 23, 2023. Reported Earnings • May 17
Full year 2023 earnings: EPS exceeds analyst expectations Full year 2023 results: EPS: JP¥220 (up from JP¥204 in FY 2022). Revenue: JP¥690.5b (up 6.4% from FY 2022). Net income: JP¥25.7b (up 7.8% from FY 2022). Profit margin: 3.7% (in line with FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.6%. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 8% per year, which means it is tracking significantly ahead of earnings growth. Upcoming Dividend • Mar 23
Upcoming dividend of JP¥50.00 per share at 2.8% yield Eligible shareholders must have bought the stock before 30 March 2023. Payment date: 27 June 2023. Payout ratio is a comfortable 17% and this is well supported by cash flows. Trailing yield: 2.8%. Lower than top quartile of Japanese dividend payers (3.6%). Higher than average of industry peers (1.7%). Reported Earnings • Feb 17
Third quarter 2023 earnings released: EPS: JP¥65.36 (vs JP¥56.01 in 3Q 2022) Third quarter 2023 results: EPS: JP¥65.36 (up from JP¥56.01 in 3Q 2022). Revenue: JP¥180.3b (up 9.4% from 3Q 2022). Net income: JP¥7.64b (up 17% from 3Q 2022). Profit margin: 4.2% (up from 4.0% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 1.7% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has increased by 3% per year. Annonce • Nov 30
Sundrug Co.,Ltd. to Report Q3, 2023 Results on Feb 14, 2023 Sundrug Co.,Ltd. announced that they will report Q3, 2023 results on Feb 14, 2023 Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 8 highly experienced directors. No independent directors (9 non-independent directors). CEO, President & Representative Director Koji Sadakata was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Upcoming Dividend • Sep 22
Upcoming dividend of JP¥50.00 per share Eligible shareholders must have bought the stock before 29 September 2022. Payment date: 06 December 2022. Payout ratio is a comfortable 36% and this is well supported by cash flows. Trailing yield: 2.1%. Lower than top quartile of Japanese dividend payers (3.7%). Higher than average of industry peers (1.6%). Annonce • Sep 02
Sundrug Co.,Ltd. (TSE:9989) agreed to acquire Daiya, K.K. from Shintaro Ito, Ichiban Co., Ltd and others. Sundrug Co.,Ltd. (TSE:9989) agreed to acquire Daiya, K.K. from Shintaro Ito, Ichiban Co., Ltd and others on September 1, 2022. For the period ended February 2022, Daiya reported Total assets of 12 billion, net worth of 2.5 billion, Revenue of 26.6 billion, Operating income of 216 million, and Net income of 418 million. The acquisition is expected to close on October 3, 2022. Annonce • Aug 28
Sundrug Co.,Ltd. to Report Q2, 2023 Results on Nov 14, 2022 Sundrug Co.,Ltd. announced that they will report Q2, 2023 results on Nov 14, 2022 Reported Earnings • Aug 15
First quarter 2023 earnings released: EPS: JP¥53.86 (vs JP¥58.18 in 1Q 2022) First quarter 2023 results: EPS: JP¥53.86 (down from JP¥58.18 in 1Q 2022). Revenue: JP¥166.5b (up 1.4% from 1Q 2022). Net income: JP¥6.30b (down 7.4% from 1Q 2022). Profit margin: 3.8% (down from 4.1% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 7.3%, compared to a 11% growth forecast for the Consumer Retailing industry in Japan. Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has increased by 4% per year. Annonce • May 29
Sundrug Co.,Ltd. to Report Q1, 2023 Results on Aug 12, 2022 Sundrug Co.,Ltd. announced that they will report Q1, 2023 results on Aug 12, 2022 Reported Earnings • May 16
Full year 2022 earnings: EPS misses analyst expectations Full year 2022 results: EPS: JP¥204 (down from JP¥217 in FY 2021). Revenue: JP¥648.7b (up 2.3% from FY 2021). Net income: JP¥23.9b (down 5.8% from FY 2021). Profit margin: 3.7% (down from 4.0% in FY 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 3.7%. Over the next year, revenue is forecast to grow 6.5%, compared to a 21% growth forecast for the retail industry in Japan. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has fallen by 2% per year. Annonce • May 15
Sundrug Co.,Ltd., Annual General Meeting, Jun 25, 2022 Sundrug Co.,Ltd., Annual General Meeting, Jun 25, 2022. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 7 highly experienced directors. No independent directors (9 non-independent directors). CEO, President & Representative Director Koji Sadakata was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Annonce • Apr 08
Sundrug Co.,Ltd. to Report Fiscal Year 2022 Results on May 13, 2022 Sundrug Co.,Ltd. announced that they will report fiscal year 2022 results on May 13, 2022 Upcoming Dividend • Mar 23
Upcoming dividend of JP¥35.00 per share Eligible shareholders must have bought the stock before 30 March 2022. Payment date: 28 June 2022. Payout ratio is a comfortable 35% and this is well supported by cash flows. Trailing yield: 2.3%. Lower than top quartile of Japanese dividend payers (3.4%). Higher than average of industry peers (1.6%). Reported Earnings • Feb 18
Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint Third quarter 2022 results: EPS: JP¥56.01 (down from JP¥61.99 in 3Q 2021). Revenue: JP¥164.9b (flat on 3Q 2021). Net income: JP¥6.55b (down 9.6% from 3Q 2021). Profit margin: 4.0% (down from 4.4% in 3Q 2021). Revenue missed analyst estimates by 2.0%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 5.9%, compared to a 14% growth forecast for the industry in Japan. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has fallen by 3% per year. Reported Earnings • Nov 15
Second quarter 2022 earnings released: EPS JP¥48.36 (vs JP¥54.98 in 2Q 2021) The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2022 results: Revenue: JP¥162.6b (up 1.8% from 2Q 2021). Net income: JP¥5.65b (down 12% from 2Q 2021). Profit margin: 3.5% (down from 4.0% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Upcoming Dividend • Sep 22
Upcoming dividend of JP¥35.00 per share Eligible shareholders must have bought the stock before 29 September 2021. Payment date: 14 December 2021. Trailing yield: 1.9%. Lower than top quartile of Japanese dividend payers (3.0%). Higher than average of industry peers (1.4%). Reported Earnings • Aug 15
First quarter 2022 earnings released: EPS JP¥58.18 (vs JP¥60.32 in 1Q 2021) The company reported a soft first quarter result with weaker earnings and profit margins, although revenues improved. First quarter 2022 results: Revenue: JP¥164.2b (up 4.7% from 1Q 2021). Net income: JP¥6.80b (down 3.5% from 1Q 2021). Profit margin: 4.1% (down from 4.5% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has fallen by 3% per year. Reported Earnings • May 18
Full year 2021 earnings released: EPS JP¥217 (vs JP¥203 in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: JP¥634.3b (up 2.7% from FY 2020). Net income: JP¥25.3b (up 6.9% from FY 2020). Profit margin: 4.0% (up from 3.8% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Upcoming Dividend • Mar 23
Upcoming dividend of JP¥35.00 per share Eligible shareholders must have bought the stock before 30 March 2021. Payment date: 22 June 2021. Trailing yield: 1.7%. Lower than top quartile of Japanese dividend payers (2.7%). Higher than average of industry peers (1.4%). Annonce • Mar 04
Sundrug Co.,Ltd. to Report Fiscal Year 2021 Results on May 14, 2021 Sundrug Co.,Ltd. announced that they will report fiscal year 2021 results on May 14, 2021 Is New 90 Day High Low • Feb 17
New 90-day low: JP¥4,020 The company is down 4.0% from its price of JP¥4,180 on 19 November 2020. The Japanese market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is JP¥5,074 per share. Reported Earnings • Feb 12
Third quarter 2021 earnings released: EPS JP¥61.99 (vs JP¥46.72 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: JP¥164.3b (up 11% from 3Q 2020). Net income: JP¥7.25b (up 33% from 3Q 2020). Profit margin: 4.4% (up from 3.7% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has fallen by 5% per year. Analyst Estimate Surprise Post Earnings • Feb 12
Revenue and earnings miss expectations Revenue missed analyst estimates by 0.02%. Earnings per share (EPS) also missed analyst estimates by 5.7%. Over the next year, revenue is forecast to grow 4.5%, compared to a 8.4% growth forecast for the Consumer Retailing industry in Japan. Is New 90 Day High Low • Dec 04
New 90-day high: JP¥4,515 The company is up 16% from its price of JP¥3,905 on 04 September 2020. The Japanese market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is JP¥4,276 per share. Annonce • Nov 29
Sundrug Co.,Ltd. to Report Q3, 2021 Results on Feb 10, 2021 Sundrug Co.,Ltd. announced that they will report Q3, 2021 results on Feb 10, 2021